APRE — Aprea Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $5.90m
- -$7.09m
- $1.50m
- 10
- 34
- 44
- 18
Annual income statement for Aprea Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.583 | 1.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 52.8 | 37.4 | 113 | 16.1 | 15.8 |
| Operating Profit | -52.8 | -37.4 | -113 | -15.5 | -14.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -53.5 | -37.1 | -113 | -14.3 | -13 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -53.5 | -37.1 | -113 | -14.3 | -13 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -53.5 | -37.1 | -113 | -14.3 | -13 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -53.5 | -37.1 | -113 | -14.3 | -13 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -50.6 | -34.9 | -22.1 | -3.95 | -2.35 |